Form 4: Imunon CEO Granted 56,187 Stock Options

Imunon, Inc. President and CEO Stacy Lindborg was granted 56,187 stock options with an exercise price of $3.95, vesting over two years.

Summary

• Stacy Lindborg, President and CEO, and a Director of Imunon, Inc. (IMNN), was granted 56,187 stock options.
• The options have an exercise price of $3.95 per share, which represents the closing price of Imunon, Inc. Common Stock on the grant date.
• The grant date for these options is January 2, 2026.
• The options vest in a staggered manner: 50% on the date of grant (January 2, 2026), 25% on the one-year anniversary of the grant date (January 2, 2027), and the remaining 25% on the second-year anniversary of the grant date (January 2, 2028).
• The expiration date for these stock options is January 2, 2036.
• Following this transaction, Stacy Lindborg beneficially owns 56,187 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the option grant aligns management's interests with shareholders, indicating a commitment to future performance. However, it's a routine compensation event and not indicative of new operational or financial news.

Positives

• The grant of stock options to the President and CEO aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The exercise price being equal to the closing price on the grant date suggests a standard incentive option grant, aiming to motivate future performance.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the granted options.

Industry Context

The grant of stock options to a President and CEO is a common practice in the biotechnology and pharmaceutical industry, as well as across many other sectors, to incentivize executive performance and align their financial interests with long-term shareholder value creation. Such compensation structures are a standard component of executive remuneration packages.

Comparison to Industry Standards

• Granting stock options to executive leadership is a widely accepted compensation practice across industries, including biotechnology, to incentivize performance and align management with shareholder interests.
• The vesting schedule, with a portion vesting immediately and the remainder over two years, is a common approach to encourage retention and sustained performance, comparable to practices at companies like Moderna or BioNTech for their executives.

Stakeholder Impact

• Shareholders: The option grant aims to align the CEO's financial incentives with shareholder value creation. Potential future dilution if options are exercised, but this is a standard aspect of equity compensation plans.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• The options will continue to vest according to the schedule: 25% on January 2, 2027, and 25% on January 2, 2028.
• Stacy Lindborg may choose to exercise the vested options at any time before the expiration date of January 2, 2036, assuming the stock price is above the exercise price of $3.95.

Key Dates

Keywords

Imunon, IMNN, Stock Options, Executive Compensation, Insider Transaction, Form 4, Stacy Lindborg